PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

作者：Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, Christina Barbara Walter, Bernhard Krämer, Eva‐Maria Grischke, Sara Yvonne Brucker · 发表于：Breast Care · 年份：2016 · DOI：10.1159/000453569 · 被引用次数：30914 · 研究领域：Cancer Immunotherapy and Biomarkers、CAR-T cell therapy research、Immunotherapy and Immune Responses

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.